Compare Danaher Corporation (DHR) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Merck & Co., Inc. — how do they compare? Danaher Corporation trades at $219.41 (market cap $152.87B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 2.3× Danaher Corporation's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Merck & Co., Inc. for 98 Days on average.
| DHR | MRK | |
|---|---|---|
Market Cap | $152.87B | $351.28B |
Volume | 5,228,698 | 7,969,665 |
Sector | Health | Health |
52-Week High | $242.05 | $156.43 |
52-Week Low | $161.91 | $82.49 |
Typical Hold Time | 69 Days | 98 Days |
Enterprise Value | $175.08B | $398.04B |
Dividend Yield | 0.74% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
